Calebin A Potentiates the Effect of 5-FU and TNF-β (Lymphotoxin α) against Human Colorectal Cancer Cells: Potential Role of NF-κB.
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Biomarkers, Tumor
/ metabolism
Cell Line
Cell Proliferation
/ drug effects
Cell Survival
Cinnamates
/ metabolism
Colonic Neoplasms
/ metabolism
Colorectal Neoplasms
/ metabolism
Fluorouracil
/ metabolism
Humans
Lymphotoxin-alpha
/ metabolism
Monoterpenes
/ metabolism
NF-kappa B
/ metabolism
Phosphorylation
Signal Transduction
/ drug effects
Transcription Factor RelA
/ metabolism
5-Fluorouracil
Calebin A
NF-κB
TNF-β (lymphotoxin)
chemosensitization
colorectal cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
31 Mar 2020
31 Mar 2020
Historique:
received:
10
03
2020
revised:
24
03
2020
accepted:
28
03
2020
entrez:
5
4
2020
pubmed:
5
4
2020
medline:
5
1
2021
Statut:
epublish
Résumé
The majority of chemotherapeutic agents stimulate NF-κB signaling that mediates cell survival, proliferation and metastasis. The natural turmeric non-curcuminoid derivate Calebin A has been shown to suppress cell growth, invasion and colony formation in colorectal cancer cells (CRC) by suppression of NF-κB signaling. Therefore, we hypothesized here that Calebin A might chemosensitize the TNF-β-treated tumor cells and potentiates the effect of 5-Fluorouracil (5-FU) in advanced CRC. CRC cells (HCT116) and their clonogenic 5-FU chemoresistant counterparts (HCT116R) were cultured in monolayer or alginate-based 3D tumor environment culture and were treated with/without Calebin A, TNF-β, 5-FU, BMS-345541 and DTT (dithiothreitol). The results showed that TNF-β increased proliferation, invasion and resistance to apoptosis in chemoresistant CRC cells. Pretreatment with Calebin A significantly chemosensitized HCT116R to 5-FU and inhibited the TNF-β-induced enhanced efforts for survival, invasion and anti-apoptotic effects. We found further that Calebin A significantly suppressed TNF-β-induced phosphorylation and nuclear translocation of p65-NF-κB, similar to BMS-345541 (specific IKK inhibitor) and NF-κB-induced tumor-promoting biomarkers (NF-κB, β1-Integrin, MMP-9, CXCR4, Ki67). This was associated with increased apoptosis in HCT116 and HCT116R cells. Furthermore, blocking of p65-NF-κB stimulation by Calebin A was imparted through the downmodulation of p65-NF-κB binding to the DNA and this suppression was turned by DTT. Our findings indicate, for the first time, that Calebin A chemosensitizes human CRC cells to chemotherapy by targeting of the p65-NF-κB signaling pathway.
Identifiants
pubmed: 32244288
pii: ijms21072393
doi: 10.3390/ijms21072393
pmc: PMC7177530
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Cinnamates
0
Lymphotoxin-alpha
0
Monoterpenes
0
NF-kappa B
0
RELA protein, human
0
Transcription Factor RelA
0
calebin-A
0
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Sci. 2007 Mar;98(3):268-74
pubmed: 17270016
Oncogene. 2015 Jul;34(27):3493-503
pubmed: 25174402
Biomedicines. 2018 Apr 17;6(2):
pubmed: 29673148
Biochem Pharmacol. 2015 Nov 1;98(1):51-68
pubmed: 26310874
Cell Stem Cell. 2014 Mar 6;14(3):275-91
pubmed: 24607403
Front Biosci. 2008 May 01;13:5094-107
pubmed: 18508572
Clin Cancer Res. 2008 Apr 1;14(7):2128-36
pubmed: 18381954
J Biol Chem. 2006 Jun 23;281(25):17023-33
pubmed: 16624823
Int J Oncol. 2009 Apr;34(4):1117-28
pubmed: 19287970
Cancer Lett. 2018 Mar 1;416:75-86
pubmed: 29246645
J Mol Med (Berl). 2004 Jul;82(7):434-48
pubmed: 15175863
Pharmaceutics. 2019 Oct 04;11(10):
pubmed: 31590262
Nutrients. 2018 Jul 12;10(7):
pubmed: 30002278
Front Biosci (Schol Ed). 2009 Jun 01;1:45-60
pubmed: 19482682
Nutrients. 2017 Sep 27;9(10):
pubmed: 28953264
Oncotarget. 2016 May 31;7(22):31892-906
pubmed: 26895469
Front Immunol. 2018 Nov 22;9:2585
pubmed: 30524422
Exp Biol Med (Maywood). 2019 Jan;244(1):1-12
pubmed: 30661394
Nat Rev Cancer. 2005 Apr;5(4):275-84
pubmed: 15803154
Curr Mol Med. 2007 Nov;7(7):619-37
pubmed: 18045141
Arch Biochem Biophys. 2016 Mar 1;593:80-9
pubmed: 26874195
J Pathol Clin Res. 2018 Apr;4(2):124-134
pubmed: 29665320
J Mol Med (Berl). 2009 Nov;87(11):1097-104
pubmed: 19727638
Biotechnol Adv. 2014 Nov 1;32(6):1053-64
pubmed: 24793420
PLoS One. 2013 Jul 16;8(7):e69760
pubmed: 23874993
Anticancer Res. 2010 Feb;30(2):319-25
pubmed: 20332435
PLoS One. 2013;8(2):e57218
pubmed: 23451189
Gastroenterology. 2010 Jun;138(6):2151-62
pubmed: 20420952
J Biol Chem. 2001 Oct 26;276(43):39713-20
pubmed: 11500489
Int J Cancer. 2019 Sep 1;145(5):1358-1370
pubmed: 30785217
Trends Biochem Sci. 2005 Jan;30(1):43-52
pubmed: 15653325
Arch Biochem Biophys. 2014 Oct 1;559:91-9
pubmed: 24946050
Curr Opin Pharmacol. 2009 Aug;9(4):351-69
pubmed: 19665429
BMC Cancer. 2015 Apr 10;15:250
pubmed: 25884903
Biochem Pharmacol. 2006 Feb 28;71(5):634-45
pubmed: 16360644
Nutr Cancer. 2009;61(6):842-6
pubmed: 20155625
Nat Rev Drug Discov. 2009 Jan;8(1):33-40
pubmed: 19116625
Biochem Pharmacol. 2010 May 1;79(9):1272-80
pubmed: 20067776
Curr Opin Pharmacol. 2006 Aug;6(4):337-44
pubmed: 16777480
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9090-5
pubmed: 8799159
Cancer Treat Rev. 2009 Aug;35(5):451-62
pubmed: 19467788
Clin Sci (Lond). 2017 Jul 5;131(15):1781-1799
pubmed: 28679846
J Basic Clin Physiol Pharmacol. 2018 Mar 28;29(2):107-122
pubmed: 29389665
J Biol Chem. 1984 Jan 10;259(1):686-91
pubmed: 6608523
Curr Pharm Biotechnol. 2011 Apr;12(4):609-20
pubmed: 21118092
Mol Cancer Ther. 2014 Oct;13(10):2422-35
pubmed: 25082961
Oncogene. 2007 Mar 1;26(10):1385-97
pubmed: 16953224
Genes Cells. 2008 May;13(5):509-20
pubmed: 18429822
J Clin Oncol. 2019 Nov 20;37(33):3111-3123
pubmed: 31593484
Biomed Pharmacother. 2014 Oct;68(8):911-6
pubmed: 25458789
Immunobiology. 2009;214(9-10):761-77
pubmed: 19616341
Nat Struct Biol. 1998 Jan;5(1):67-73
pubmed: 9437432
J Oncol Pharm Pract. 2018 Oct;24(7):501-506
pubmed: 28714378
Oncologist. 2006 Oct;11(9):973-80
pubmed: 17030637
Biochemistry. 2009 Aug 4;48(30):7271-8
pubmed: 19591457
Front Immunol. 2018 Sep 27;9:2160
pubmed: 30319623
J Biol Chem. 1985 Feb 25;260(4):2345-54
pubmed: 3871770
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Int J Mol Sci. 2019 Oct 09;20(20):
pubmed: 31600949
Arch Pharm Res. 2018 Jan;41(1):1-13
pubmed: 29230689
Crit Rev Food Sci Nutr. 2017 Sep 2;57(13):2889-2895
pubmed: 26528921
Onco Targets Ther. 2018 Apr 11;11:2063-2073
pubmed: 29695914
Nutrients. 2019 Dec 01;11(12):
pubmed: 31805741
Mol Pharmacol. 2011 Nov;80(5):769-81
pubmed: 21795584
Blood. 2019 Mar 28;133(13):1489-1494
pubmed: 30696620
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Transl Oncol. 2009 Dec;2(4):321-8
pubmed: 19956394
Phytomedicine. 2017 Oct 15;34:171-181
pubmed: 28899500
J Clin Pathol. 2018 Feb;71(2):110-116
pubmed: 28942428
Eur J Pharmacol. 2008 Sep 4;591(1-3):252-8
pubmed: 18619958
Oncologist. 2018 May;23(5):573-579
pubmed: 29371477
Nutrients. 2019 Mar 26;11(3):
pubmed: 30917533
Cell Stem Cell. 2007 Oct 11;1(4):389-402
pubmed: 18371377
Nat Rev Cancer. 2009 May;9(5):361-71
pubmed: 19343034
Mol Nutr Food Res. 2013 Sep;57(9):1529-42
pubmed: 23847105
Blood. 2003 Feb 1;101(3):1053-62
pubmed: 12393461
Oncol Lett. 2019 Dec;18(6):6869-6876
pubmed: 31807190